"Animal models revealed that although experimental SARS and MERS vaccines could create high amounts of antibodies, when challenged with exposure to the wild viruses they were supposed to be protected against, the animals instead developed severe, even lethal disease reactions.”

 

https://www.govinfo.gov/content/pkg/CHRG-116hhrg39909/html/CHRG-116hhrg39909.htm

https://www.govinfo.gov/content/pkg/CHRG-116hhrg39909/html/CHRG-116hhrg39909.htm 

HOTEZ: “Because what happens with certain types of respiratory virus vaccines, you get immunized, and then, when you get actually exposed to the virus, you get this kind of paradoxical
immune enhancement phenomenon.” [Pathogenic Priming]

+++

So we partnered with a group at the New York Blood Center and the Galveston National Laboratory to take on the big scientific challenge of coronavirus vaccines.

And I say a scientific challenge because one of the things that we’re not hearing a lot about is the unique potential safety problem of coronavirus vaccines.

This was first found in the early 1960s, with the respiratory syncytial virus (RSV) vaccines that–and
it was done here in Washington with the NIH and Children’s National Medical Center, that some of those kids who got the vaccine, actually did worse, and I believe there were two deaths as–in the consequence of that study.

Because what happens with certain types of respiratory virus vaccines, you get immunized, and then, when you get actually exposed to the virus, you get this kind of paradoxical
immune enhancement phenomenon.

And what–how–and we don’t entirely understand the basis of it, but we recognize that it’s
a real problem for certain respiratory virus vaccines.

That
killed the RSV program for decades.

Now the Gates Foundation is taking it up again, but when we started developing coronavirus vaccines, and our colleagues, we noticed in laboratory animals that they started to show some of the same immune pathology that resembled what had happened 50 years earlier, so we said, oh, my God, this is going to be problematic.

But we collaborated with a unique group that figured out how to solve the problem, that if you narrow it down to the smallest sub-unit, the piece that–of–what’s called the
receptor binding domain, that docks with the receptor, you get protection, and you don’t get that immune enhancement phenomena. So we were really excited about that, and we proposed this to the National Institute of Allergy and
Infectious Diseases (NIAID). They funded it, and we wound up actually making and manufacturing, in collaboration with Walter Reed Army Institute of Research, a first generation SARS vaccine. So SARS was the one that emerged in 2003, and then this new one, of course, we call the SARS-2 coronavirus.
We had it manufactured, but then we could never get the investment to take it beyond that. And then–so that was really unfortunate, because we had the vaccine ready to go, but we couldn’t move it into the clinic because of lack of funding, because by then nobody was interested in coronavirus vaccines. When the Chinese started putting up the data on bioarchive in January/February, we saw very close homology between the two, and realized that we may be sitting on a very attractive coronavirus vaccine. Now we’re working with–again with NIH, and we’ll work with BARDA (Biomedical Advanced Research and Development Authority) and others, to get the funding, but now we’ll have that lag. And these clinical trials are not going to
go quickly because of that immune enhancement. It’s going to take time.
And so, you know, all–unfortunately, some of my
colleagues in the biotech industry are making these inflated claims, you know, you’ve seen this in the newspapers, we’re going to have this vaccine in weeks, or–in this and that. What they’re really saying is they could move a vaccine to clinical
trials, but this will not go quickly because, as we start
vaccinating human volunteers, especially in areas where we have community transmission, we’re going to have to proceed very slowly, very cautiously. The FDA (Food and Drug Administration) is on top of that. They have a great team in place at the
Center for Biologics Evaluation Research (CBER). They’re aware of the problem, but it’s not going to go quickly. We are going
to have to follow this very slowly, cautiously, to make certain we’re not seeing that immune enhancement.

+++

https://www.informedchoicewa.org/covid-19/covid-19-autoimmunity-via-pathogenic-priming/

https://www.informedchoicewa.org/covid-19/covid-19-autoimmunity-via-pathogenic-priming/ 

“There has never been a successful vaccine for SARS or MERS, two viruses related to SARS-CoV-2 (the virus that can lead to COVID-19 disease.)

Animal models revealed that although experimental SARS and MERS vaccines could create high amounts of antibodies, when challenged with exposure to the wild viruses they were supposed to be protected against, the animals instead developed severe, even lethal disease reactions.”

#SARSCoV2

[Don’t skip animal models; Vaccinated animals need to be “challenged” with exposure to the wild virus]